A network meta-analysis of endocrine adverse events induced by immune checkpoint inhibitors in colorectal cancer

• by Boyu Chen, Jing Liu, Kexin Gan, Liqun Yang, Peng Qiu, Boqing Ma, Wen Chen

• July 10, 2026

Coding for Ocular Tumors

Ocular tumor coding can be challenging because ocular oncology often involves evolving lesions, diagnostic uncertainty, and terminology that does not always translate cleanly into ICD-10-CM codes. Understanding how to distinguish benign, malignant, in situ, and uncertain histologic behavior neoplasms is essential for accurate coding, medical necessity, and audit defensibility.

• by Elizabeth Cifers, MBA, MSW, CHC, CPC

• September 1, 2026

• 4 min

This Week’s CGT News: Bristol Myers Ends Cellares Manufacturing Agreement

A first-in-human study reduces stem-cell collection and manufacturing times, Bristol Myers ends its Breyanzi agreement with Cellares, and two approaches strengthen CAR T-cell activity against solid tumors

• August 31, 2026

• 5 min

Trastuzumab deruxtecan treatment for HER2-low metastatic scrotal extramammary Paget’s disease with bone marrow involvement: a case report

• by Yi Bao, Lei Zhang, Fenfen Jiang, Juanfen Mo

• September 1, 2026